Drugs / Paxlovid
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Paxlovid | — | 2022-01-28 | europa.eu ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT05532852 | Jul 2022 → Jun 2023 | pneumonia | Ruijin Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT05642910 Comparator | Oct 2022 → Jan 2023 | COVID-19 | Southeast University, China | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Paxlovid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05532852 ↗ |
| Route | Oral | “Paxlovid is a Pfizer-developed oral new drug” NCT05532852 ↗ |